Consultation on a proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the review queue
Current status: Open
Opened on July 15, 2026 and will close to new input on September 12, 2026
Health Canada is seeking feedback on a proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the regulatory review queue. We invite stakeholders to provide feedback on the proposed pilot, including its scope, eligibility criteria and attestation approach.
Read the proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the review queue notice to learn more about the proposed pilot.
Feedback received through the consultation will be used to refine the proposed approach and inform the design and implementation of the pilot.
Join in: How to participate
You can provide your feedback in the following ways:
Send us an email
Send an email to hpfb.engagement-mobilisation.dgpsa@hc-sc.gc.ca with your ideas or comments to make yourself heard.
Participate by mail
Send a letter with your ideas and input to the address in contact us below.
Who is the focus of this consultation
We will engage with:
- Academia
- Health system partners
- Health care professionals
- Interested members of the public
- Patient Involvement organizations
- Industry and industry associations (human and veterinary)
Key questions for discussion
Through this consultation, Health Canada is seeking feedback on:
- a targeted, time-limited pilot to prioritize certain generic drug submissions involving domestic manufacturing with the regulatory review queue
Input received will be used to refine the proposed approach and inform the design and implementation of the pilot.
Contact us
Health Canada
150 Tunney's Pasture Driveway
Ottawa, Ontario K1A 0K9
Address locator: 302B
Email: hpfb.engagement-mobilisation.dgpsa@hc-sc.gc.ca
From: Health Canada